Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria E Rodriguez-Ruiz

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Journal for Immunotherapy of Cancer|November 26, 2021
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacyMaite Alvarez, Carmen Molina, Carlos E De Andrea, et al.
Cancer Research|June 27, 2015
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient MiceMiguel F Sanmamed, Inmaculada Rodriguez, Kurt A Schalper, et al.
Journal for Immunotherapy of Cancer|August 30, 2024
NKG2C/<i>KLRC2</i> tumor cell expression enhances immunotherapeutic efficacy against glioblastomaOlaya de Dios, M Angeles Ramírez-González, Irene Gómez-Soria, et al.
Journal for Immunotherapy of Cancer|February 11, 2025
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor modelsEneko Garate-Soraluze, Irantzu Serrano-Mendioroz, Leticia Fernández-Rubio, et al.
Molecular Cancer|March 23, 2024
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancerAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Signal Transduction and Targeted Therapy|March 18, 2025
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial resultsAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular TrapsAlvaro Teijeira, Saray Garasa, Maria C Ochoa, et al.
Nature Medicine|February 12, 2019
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastomaKurt A Schalper, Maria E Rodriguez-Ruiz, Ricardo Diez-Valle, et al.
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
The Journal of Clinical Investigation|May 1, 2026
Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancerAlvaro Lopez-Janeiro, José González-Gomariz, Fadi Issa, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|November 26, 2021
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacyMaite Alvarez, Carmen Molina, Carlos E De Andrea, et al.
Cancer Research|June 27, 2015
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient MiceMiguel F Sanmamed, Inmaculada Rodriguez, Kurt A Schalper, et al.
Journal for Immunotherapy of Cancer|August 30, 2024
NKG2C/<i>KLRC2</i> tumor cell expression enhances immunotherapeutic efficacy against glioblastomaOlaya de Dios, M Angeles Ramírez-González, Irene Gómez-Soria, et al.
Journal for Immunotherapy of Cancer|February 11, 2025
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor modelsEneko Garate-Soraluze, Irantzu Serrano-Mendioroz, Leticia Fernández-Rubio, et al.
Molecular Cancer|March 23, 2024
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancerAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Signal Transduction and Targeted Therapy|March 18, 2025
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial resultsAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular TrapsAlvaro Teijeira, Saray Garasa, Maria C Ochoa, et al.
Nature Medicine|February 12, 2019
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastomaKurt A Schalper, Maria E Rodriguez-Ruiz, Ricardo Diez-Valle, et al.
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
The Journal of Clinical Investigation|May 1, 2026
Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancerAlvaro Lopez-Janeiro, José González-Gomariz, Fadi Issa, et al.
Pageof 4